细胞焦亡在糖尿病肾脏病中的作用及机制研究进展

冉珍琴; 刘泽慧; 杨蓉; 王子宙; 陈栎昕; 韩睿

细胞焦亡在糖尿病肾脏病中的作用及机制研究进展

昆明医科大学第一附属医院国际医学部，云南昆明　650032

基金项目: 云南省糖尿病及慢性并发症诊疗关键技术创新应用国际联合实验室（202503AP140036）；云南省科技厅-昆明医科大学基础研究计划项目（202501AY070001-009）；云南省“兴滇英才支持计划”（名医专项）（XDYC-MY-2022-0004）；云南省卫生健康委员会医学领军人才（L-2019015）；昆明医科大学教育教学研究课题重点项目（2024-JY-Z-13）。

详细信息

作者简介:
冉珍琴（1999～），女，土家族，贵州铜仁人，在读硕士研究生，主要从事内分泌与代谢医学研究工作

通讯作者:
韩睿，E-mail：13529365266@163.com

中图分类号: R587.2
计量
- 文章访问数: 47
- HTML全文浏览量: 33
- PDF下载量: 12
- 被引次数: 0
出版历程
- 收稿日期: 2025-11-17
- 网络出版日期: 2026-01-06

Research Progress on the Role and Mechanism of Pyroptosis in Diabetic Kidney Disease

Department of International Medicine，The First Affiliated Hospital of Kunming Medical University，Kunming Yunnan 650032，China

摘要

摘要: 糖尿病肾脏病（diabetic kidney disease，DKD）是糖尿病最常见的微血管并发症之一，属于无菌性炎症性疾病。细胞焦亡（pyroptosis）是一种由炎症小体和半胱天冬酶（caspase）家族介导的炎症性程序性细胞死亡方式，近年来被证实在DKD发生发展中发挥着关键作用。高血糖等刺激可通过激活NLRP3炎症小体及相关信号通路诱导肾脏固有细胞焦亡，进一步放大局部炎症反应、促进肾纤维化进程，最终导致肾功能进行性恶化。本文综述了细胞焦亡的分子机制及其在DKD中的研究进展，探讨以焦亡通路为靶点的潜在干预策略，为DKD的防治提供新的理论依据与治疗思路。
- 细胞焦亡 /
- 糖尿病肾病 /
- 肾纤维化 /
- 研究进展
Abstract: Diabetic kidney disease （DKD） is one of the most common microvascular complications of diabetes mellitus, and it is categorized as a sterile inflammatory disease. Pyroptosis is an inflammatory form of programmed cell death mediated by inflammasomes and the cysteine-aspartic acid protease （Caspase） family, which has been demonstrated to play a crucial role in the pathogenesis and progression of DKD in recent years. Stimuli such as hyperglycemia can induce pyroptosis in intrinsic renal cells by activating the NLRP3 inflammasome and related signaling pathways, which further amplifies local inflammatory responses, promotes the process of renal fibrosis, and ultimately leads to progressive deterioration of renal function. This review systematically summarized the molecular mechanisms of pyroptosis and the research progress of pyroptosis in DKD, in order to explore potential intervention strategies targeting the pyroptosis pathway, and provide new theoretical basis and therapeutic ideas for the prevention and treatment of DKD.
- Pyroptosis /
- Diabetic kidney disease /
- Renal fibrosis /
- Research progress

HTML全文

图 1 不同细胞焦亡途径示意图

Figure 1. Diagram showing different pyroptotic pathways

下载: 全尺寸图片幻灯片

图 2 细胞焦亡驱动DKD肾纤维化机制图

Figure 2. Diagram of the mechanism of renal fibrosis driven by pyroptosis in DKD

下载: 全尺寸图片幻灯片

参考文献(50)

[1]	Joumaa J P, Raffoul A, Sarkis C, et al. Mechanisms, biomarkers, and treatment approaches for diabetic kidney disease: current insights and future perspectives[J]. J Clin Med, 2025, 14(3): 727.
[2]	He Y, Wang X, Li L, et al. Global, regional, and national prevalence of chronic type 2 diabetic kidney disease from 1990 to 2021: a trend and health inequality analyses based on the global burden of disease study 2021[J]. J Diabetes, 2025, 17(5): e70098. doi: 10.1111/1753-0407.70098
[3]	Zhang H, Wang K, Zhao H, et al. Diabetic kidney disease: from pathogenesis to multimodal therapy-current evidence and future directions[J]. Front Med, 2025, 12: 1631053.
[4]	Efiong E E, Maedler K, Effa E, et al. Decoding diabetic kidney disease: a comprehensive review of interconnected pathways, molecular mediators, and therapeutic insights[J]. Diabetol Metab Syndr, 2025, 17(1): 192.
[5]	Fang B, Huang W, Du S, et al. The inflammatory cell death in diabetic kidney disease: integrating multifactorial mechanisms into novel therapeutics[J]. Int J Mol Sci, 2025, 26(22): 11033. doi: 10.3390/ijms262211033
[6]	Chen Y, Chen R, Ji X, et al. NLRP3 inflammasome-mediated pyroptosis in diabetic nephropathy: pathogenic mechanisms and therapeutic Targets[J]. J Inflamm Res, 2025, 18: 8399-8418.
[7]	Zheng X, Wan J, Tan G. The mechanisms of NLRP3 inflammasome/pyroptosis activation and their role in diabetic retinopathy[J]. Front Immunol, 2023, 14: 1151185. doi: 10.3389/fimmu.2023.1151185
[8]	Vasudevan S O, Behl B, Rathinam V A. Pyroptosis-induced inflammation and tissue damage[J]. Semin Immunol, 2023, 69: 101781. doi: 10.1016/j.smim.2023.101781
[9]	Wright S S, Vasudevan S O, Rathinam V A. Mechanisms and consequences of noncanonical inflammasome-mediated pyroptosis[J]. J Mol Biol, 2022, 434(4): 167245. doi: 10.1016/j.jmb.2021.167245
[10]	Du T, Gao J, Li P, et al. Pyroptosis, metabolism, and tumor immune microenvironment[J]. Clin Transl Med, 2021, 11(8): e492.
[11]	Rao Z, Zhu Y, Yang P, et al. Pyroptosis in inflammatory diseases and cancer[J]. Theranostics, 2022, 12(9): 4310-4329.
[12]	Swanson K V, Deng M, Ting J P. The NLRP3 inflammasome: Molecular activation and regulation to therapeutics[J]. Nat Rev Immunol, 2019, 19(8): 477-489. doi: 10.1038/s41577-019-0165-0
[13]	Fu J, Wu H. Structural mechanisms of NLRP3 inflammasome assembly and activation[J]. Annu Rev Immunol, 2023, 41: 301-316. doi: 10.1146/annurev-immunol-081022-021207
[14]	Zheng X, Chen W, Gong F, et al. The role and mechanism of pyroptosis and potential therapeutic targets in sepsis: A review[J]. Front Immunol, 2021, 12: 711939. doi: 10.3389/fimmu.2021.711939
[15]	Bauernfried S, Hornung V. Human NLRP1: From the shadows to center stage[J]. J Exp Med, 2022, 219(1): e20211405. doi: 10.1084/jem.20211405
[16]	Romberg N, Vogel T P, Canna S W. NLRC4 inflammasomopathies[J]. Curr Opin Allergy Clin Immunol, 2017, 17(6): 398-404. doi: 10.1097/ACI.0000000000000396
[17]	Wang B, Tian Y, Yin Q. AIM2 inflammasome assembly and signaling[J]. Adv Exp Med Biol, 2019, 1172: 143-155. doi: 10.1007/978-981-13-9367-9_7
[18]	Yu D, Zheng S, Sui L, et al. The role of AIM2 in inflammation and tumors[J]. Front Immunol, 2024, 15: 1466440. doi: 10.3389/fimmu.2024.1466440
[19]	Oh S, Lee J, Oh J, et al. Integrated NLRP3, AIM2, NLRC4, Pyrin inflammasome activation and assembly drive PANoptosis[J]. Cell Mol Immunol, 2023, 20(12): 1513-1526.
[20]	Liu Z, Wang C, Lin C. Pyroptosis as a double-edged sword: The pathogenic and therapeutic roles in inflammatory diseases and cancers[J]. Life Sci, 2023, 318: 121498. doi: 10.1016/j.lfs.2023.121498
[21]	Abu Khweek A, Amer A O. Pyroptotic and non-pyroptotic effector functions of caspase-11[J]. Immunol Rev, 2020, 297(1): e12910.
[22]	Rühl S, Broz P. Caspase-11 activates a canonical NLRP3 inflammasome by promoting K(+) efflux[J]. Eur J Immunol, 2015, 45(10): 2927-2936.
[23]	González P, Lozano P, Ros G, et al. Hyperglycemia and oxidative stress: An integral, updated and critical overview of their metabolic interconnections[J]. Int J Mol Sci, 2023, 24(11): 9352.
[24]	Russell-Guzmán J, Américo-Da Silva L, Cadagan C, et al. Activation of the ROS/TXNIP/NLRP3 pathway disrupts insulin-dependent glucose uptake in skeletal muscle of insulin-resistant obese mice[J]. Free Radic Biol Med, 2024, 222: 187-198. doi: 10.1016/j.freeradbiomed.2024.06.011
[25]	Ji K, Chen L, Wang X, et al. Integrating single-cell RNA sequencing with spatial transcriptomics reveals an immune landscape of human myometrium during labour[J]. Clin Transl Med, 2023, 13(4): e1234. doi: 10.1002/ctm2.1234
[26]	Liu P, Zhang Z, Li Y. Relevance of the pyroptosis-related inflammasome pathway in the pathogenesis of diabetic kidney disease[J]. Front Immunol, 2021, 12: 603416. doi: 10.3389/fimmu.2021.603416
[27]	Liu Y, Lei H, Zhang W, et al. Pyroptosis in renal inflammation and fibrosis: Current knowledge and clinical significance[J]. Cell Death Dis, 2023, 14: 472. doi: 10.1038/s41419-023-06005-6
[28]	Huang R, Fu P, Ma L. Kidney fibrosis: From mechanisms to therapeutic medicines[J]. Signal Transduct Target Ther, 2023, 8(1): 129. doi: 10.1038/s41392-023-01379-7
[29]	胡雪茹. 吴茱萸次碱对糖尿病肾病足细胞损伤的保护作用及相关机制研究[D]. 合肥: 安徽医科大学, 2022.
[30]	Feng L, Feng Y, Ren Q, et al. Mesangial cells in diabetic kidney disease: from mechanisms to therapeutic implications[J]. Int J Biol Sci, 2025, 21(11): 4762-4781. doi: 10.7150/ijbs.114907
[31]	Hu S, Hang X, Wei Y, et al. Crosstalk among podocytes, glomerular endothelial cells and mesangial cells in diabetic kidney disease: an updated review[J]. Cell Commun Signal, 2024, 22(1): 136.
[32]	Williams B M, Cliff C L, Lee K, et al. The role of the NLRP3 inflammasome in mediating glomerular and tubular injury in diabetic nephropathy[J]. Front Physiol, 2022, 13: 907504. doi: 10.3389/fphys.2022.907504
[33]	Thomas H Y, Ford Versypt A N. Pathophysiology of mesangial expansion in diabetic nephropathy: Mesangial structure, glomerular biomechanics, and biochemical signaling and regulation[J]. J Biol Eng, 2022, 16(1): 19.
[34]	Ostendorf T, Boor P, van Roeyen C R C, et al. Platelet-derived growth factors (PDGFs) in glomerular and tubulointerstitial fibrosis[J]. Kidney Int Suppl, 2014, 4(1): 65-69.
[35]	Melchinger I, Guo K, Li X, et al. VCAM-1 mediates proximal tubule-immune cell cross talk in failed tubule recovery during AKI-to-CKD transition[J]. Am J Physiol Renal Physiol, 2024, 327(4): F610-F622. doi: 10.1152/ajprenal.00076.2024
[36]	Thomas J M, Ling Y H, Huuskes B, et al. IL-18 (interleukin-18) produced by renal tubular epithelial cells promotes renal inflammation and injury during deoxycorticosterone/salt-induced hypertension in mice[J]. Hypertension, 2021, 78(5): 1296-1309. doi: 10.1161/HYPERTENSIONAHA.120.16437
[37]	Meng X M, Nikolic-Paterson D J, Lan H Y. TGF-β: The master regulator of fibrosis[J]. Nat Rev Nephrol, 2016, 12(6): 325-338. doi: 10.1038/nrneph.2016.48
[38]	Yu X Y, Sun Q, Zhang Y M, et al. TGF-β/smad signaling pathway in tubulointerstitial fibrosis[J]. Front Pharmacol, 2022, 13: 860588. doi: 10.3389/fphar.2022.860588
[39]	Wang W, Wang X, Chun J, et al. Inflammasome-independent NLRP3 augments TGF-β signaling in kidney epithelium[J]. J Immunol, 2013, 190(3): 1239-1249. doi: 10.4049/jimmunol.1201959
[40]	Liu Y, Lei H, Zhang W, et al. Pyroptosis in renal inflammation and fibrosis: Current knowledge and clinical significance[J]. Cell Death Dis, 2023, 14(7): 472. doi: 10.1038/s41419-023-06005-6
[41]	Coll R C, Hill J R, Day C J, et al. MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition[J]. Nat Chem Biol, 2019, 15(6): 556-559. doi: 10.1038/s41589-019-0277-7
[42]	Jiang H, He H, Chen Y, et al. Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders[J]. J Exp Med, 2017, 214(11): 3219-3238. doi: 10.1084/jem.20171419
[43]	Burdette B E, Esparza A N, Zhu H, et al. Gasdermin D in pyroptosis[J]. Acta Pharm Sin B, 2021, 11(9): 2768-2782. doi: 10.1016/j.apsb.2021.02.006
[44]	Jin Y, Liu Y, Xu L, et al. Novel role for caspase 1 inhibitor VX765 in suppressing NLRP3 inflammasome assembly and atherosclerosis via promoting mitophagy and efferocytosis[J]. Cell Death Dis, 2022, 13(5): 512. doi: 10.1038/s41419-022-04966-8
[45]	Liu Z, Wang C, Rathkey J K, et al. Structures of the gasdermin D C-terminal domains reveal mechanisms of autoinhibition[J]. Structure, 2018, 26(5): 778-784. doi: 10.1016/j.str.2018.03.002
[46]	Dai Z, Liu W C, Chen X Y, et al. Gasdermin D-mediated pyroptosis: Mechanisms, diseases, and inhibitors[J]. Front Immunol, 2023, 14: 1178662.
[47]	Hu J J, Liu X, Xia S, et al. FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation[J]. Nat Immunol, 2020, 21(7): 736-745. doi: 10.1038/s41590-020-0669-6
[48]	Zahid A, Li B, Kombe A J K, et al. Pharmacological inhibitors of the NLRP3 inflammasome[J]. Front Immunol, 2019, 10: 2538. doi: 10.3389/fimmu.2019.02538
[49]	Suganya N, Dornadula S, Chatterjee S, et al. Quercetin improves endothelial function in diabetic rats through inhibition of endoplasmic reticulum stress-mediated oxidative stress[J]. Eur J Pharmacol, 2018, 819: 80-88. doi: 10.1016/j.ejphar.2017.11.034
[50]	Choe J Y, Kim S K. Quercetin and ascorbic acid suppress fructose-induced NLRP3 inflammasome activation by blocking intracellular shuttling of TXNIP in human macrophage cell lines[J]. Inflammation, 2017, 40(3): 980-994. doi: 10.1007/s10753-017-0542-4

相关文章(20)

[1]	杨明, 吕小星, 徐顺利. TP53通过MMP1信号通路促进NIH-3T3焦亡并抑制细胞侵袭及迁移, 昆明医科大学学报. 2025, 46(6): 54-63. doi: 10.12259/j.issn.2095-610X.S20250607
[2]	李文超, 李雪, 林珊珊, 马昀, 康国瑞, 陈烨. 三芪口服液对糖尿病肾病大鼠糖酵解、肾脏细胞凋亡及Keap1-Nrf2 信号通路的影响, 昆明医科大学学报. 2025, 46(12): 1-7.
[3]	赵晓妤, 张敏雁, 陈惠雅, 崔婷婷, 黄钰寒, 徐丹. 细胞焦亡相关TLR4信号通路在光线性角化病向皮肤鳞癌进展中的表达, 昆明医科大学学报. 2025, 46(11): 11-17. doi: 10.12259/j.issn.2095-610X.S20251102
[4]	张怡雯, 王锡铭, 李子龙, 张新章, 陈昌贤, 刘为军, 张振勇. 人工智能在肛肠疾病诊治中的研究进展, 昆明医科大学学报. 2024, 45(2): 1-6. doi: 10.12259/j.issn.2095-610X.S20240201
[5]	王玲, 秦祥川, 李金秋, 阿仙姑·哈斯木. CD147通过AIM2炎症小体介导宫颈癌细胞焦亡和增殖, 昆明医科大学学报. 2024, 45(1): 15-21. doi: 10.12259/j.issn.2095-610X.S20240103
[6]	陈潇. 基于决策树分类模型的糖尿病肾病进展预测量表的研制, 昆明医科大学学报. 2024, 45(8): 109-116. doi: 10.12259/j.issn.2095-610X.S20240816
[7]	王静, 米弘瑛, 张熠, 李丽, 余建华, 刘丽巧, 刘庆瑜, 王立伟. 细胞焦亡参与早期子鼠坏死性小肠结肠炎的发病, 昆明医科大学学报. 2023, 44(1): 25-30. doi: 10.12259/j.issn.2095-610X.S20230124
[8]	熊煜欣, 杨莹. 糖尿病肾小管病研究进展, 昆明医科大学学报. 2023, 44(9): 148-154. doi: 10.12259/j.issn.2095-610X.S20230920
[9]	陈怡璇, 王琳, 夏秀宏, 彭在坤, 丁奕, 史润娇, 雷学芬. 自噬在肝细胞癌中的作用机制研究进展, 昆明医科大学学报. 2023, 44(4): 159-164. doi: 10.12259/j.issn.2095-610X.S20230416
[10]	赵玲, 钟洪玲, 高歆茹, 李妹, 毛婷婷, 李荣勇, 柯亭羽. SGLT-2抑制剂延缓糖尿病肾病进展的临床疗效, 昆明医科大学学报. 2023, 44(5): 60-65. doi: 10.12259/j.issn.2095-610X.S20230527
[11]	张桂煊, 石鑫, 李伟, 叶淑华. 影像组学在肾上腺肿瘤中的研究进展, 昆明医科大学学报. 2022, 43(3): 142-147. doi: 10.12259/j.issn.2095-610X.S20220324
[12]	龙熙翠, 刘贝贝, 卢绍波, 李志红, 金文娇, 陆金芝, 韩雪松. 细胞焦亡因子Caspase-1、IL-1β与IL-18在子宫内膜息肉组织中的表达和意义, 昆明医科大学学报. 2021, 42(9): 51-56. doi: 10.12259/j.issn.2095-610X.S20210917
[13]	王小莹, 刘作金, 申丽娟. 缺血再灌注损伤与细胞焦亡的相关性研究进展, 昆明医科大学学报. 2020, 41(12): 142-147. doi: 10.12259/j.issn.2095-610X.S20201240
[14]	杨丹. 间充质干细胞的旁分泌作用对糖尿病肾病的影响, 昆明医科大学学报. 2016, 37(10): -.
[15]	李会芳. 糖尿病肾病易感基因位点多态性的交互作用, 昆明医科大学学报. 2015, 36(06): -1.
[16]	张席军. 中期因子及CTGF与糖尿病肾病患者纤维化相关因子关系探讨, 昆明医科大学学报. 2015, 36(04): -1.
[17]	王兴宁. 尿微量白蛋白与肌酐比值在2型糖尿病早期肾损伤中的应用, 昆明医科大学学报. 2014, 35(09): -1.
[18]	唐丽丽. GLP-1与2型糖尿病及糖尿病肾病的相关性研究, 昆明医科大学学报. 2012, 33(01): -.
[19]	. 丝氨酸蛋白酶抑制剂对新生血管抑制作用的研究进展, 昆明医科大学学报. 2011, 32(04): -.
[20]	李梅蕊. PC-1基因多态性与2型糖尿病及糖尿病肾病的相关性研究, 昆明医科大学学报. 2008, 29(01): -.